China Universal Asset Management Co. Ltd. Invests $26,000 in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

China Universal Asset Management Co. Ltd. acquired a new stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTAFree Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,494 shares of the biotechnology company’s stock, valued at approximately $26,000.

Several other large investors have also bought and sold shares of ENTA. US Bancorp DE raised its position in Enanta Pharmaceuticals by 4,933.7% in the third quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 4,243 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Enanta Pharmaceuticals in the 3rd quarter worth approximately $122,000. Quest Partners LLC raised its holdings in shares of Enanta Pharmaceuticals by 65.0% in the 3rd quarter. Quest Partners LLC now owns 19,123 shares of the biotechnology company’s stock worth $198,000 after purchasing an additional 7,535 shares in the last quarter. Valence8 US LP acquired a new stake in Enanta Pharmaceuticals during the third quarter valued at approximately $207,000. Finally, Barclays PLC boosted its holdings in Enanta Pharmaceuticals by 294.2% during the third quarter. Barclays PLC now owns 27,438 shares of the biotechnology company’s stock worth $285,000 after buying an additional 20,478 shares in the last quarter. Institutional investors own 94.99% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Jay R. Luly sold 5,142 shares of the firm’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $8.06, for a total transaction of $41,444.52. Following the completion of the sale, the chief executive officer now directly owns 801,638 shares of the company’s stock, valued at $6,461,202.28. This trade represents a 0.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 13.89% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ENTA. HC Wainwright reduced their price objective on Enanta Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, December 24th. Robert W. Baird decreased their price target on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a research report on Tuesday, November 26th. Finally, JMP Securities restated a “market outperform” rating and set a $21.00 price objective (down previously from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $17.25.

Get Our Latest Analysis on Enanta Pharmaceuticals

Enanta Pharmaceuticals Trading Down 1.0 %

NASDAQ:ENTA opened at $5.12 on Wednesday. Enanta Pharmaceuticals, Inc. has a 1-year low of $4.71 and a 1-year high of $17.80. The firm has a market capitalization of $109.21 million, a price-to-earnings ratio of -0.93 and a beta of 0.54. The business’s fifty day moving average price is $6.23 and its 200 day moving average price is $9.96.

Enanta Pharmaceuticals (NASDAQ:ENTAGet Free Report) last issued its earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). The business had revenue of $14.60 million during the quarter, compared to analyst estimates of $17.99 million. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. Enanta Pharmaceuticals’s revenue for the quarter was down 22.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.33) EPS. Equities analysts forecast that Enanta Pharmaceuticals, Inc. will post -5.05 earnings per share for the current year.

About Enanta Pharmaceuticals

(Free Report)

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.

Read More

Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTAFree Report).

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.